Regeneron Pharmaceuticals Inc (REGN.OQ)
26 Apr 2018
* REGENERON PHARMACEUTICALS INC SAYS PRESIDENT AND CEO LEONARD S. SCHLEIFER'S 2017 TOTAL COMPENSATION WAS $26.5 MILLION VERSUS $28.3 MILLION IN 2016 – SEC FILING
PARIS The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.
PARIS, April 3 The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.
BRIEF-EMA To Review Dupixent As Potential Treatment For Inadequately Controlled Moderate-To Severe Asthma
* EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA
BRIEF-Regeneron, Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis
* REGENERON AND ALNYLAM PHARMACEUTICALS ANNOUNCE COLLABORATION TO DISCOVER NEW TREATMENTS FOR NONALCOHOLIC STEATOHEPATITIS (NASH)
BRIEF-Novartis files patent infringement against Regeneron over latter's manufacture of Eylea, Zaltrap
March 19 Novartis files patent infringement lawsuit against regeneron over latter's manufacturing of eylea, zaltrap -- court filing Novartis alleges that eylea, zaltrap incorporate technology covered by one or more claims of a patent it holds Novartis says the patent in question dates from 1997 and is called 'vector for expression of a polypeptide in a mammalian cell' Novartis seeks compensatory and triple damages for renegeron's alleged willful patent infringement, in a lawsuit file
BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial
* EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL
A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.
Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.
March 10 Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.
|Novartis AG (NOVN.S)||CHF76.10||+0.86|
|Pfizer Inc. (PFE.N)||$36.85||+0.17|
|Bayer AG (BAYGn.DE)||€97.34||-0.13|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€66.31||+0.44|
|Merck & Co., Inc. (MRK.N)||$59.41||-0.22|
|Amgen, Inc. (AMGN.OQ)||$175.37||+0.54|
|Roche Holding Ltd. (ROG.S)||CHF218.10||+0.35|
|Roche Holding Ltd. (RO.S)||CHF223.00||+0.40|
|Eli Lilly And Co (LLY.N)||$82.55||+1.41|